Previous research (the Gynecologic Oncology Group's GOG181B trial) has suggested that trastuzumab is inactive in HER2 / neu - expressing
endometrial carcinomas, and in the current study, nearly half
of the participants «ultimately did not have tumoral HER2 / neu gene amplification,» Dr. Santin said.
Currently, the CDK9 inhibitor flavopiridol is being evaluated in several phase I and II clinical trials for its anti-cancer effects either as a single agent or in combination with other drugs in treatment
of esophageal cancer, B - cell chronic lymphocytic leukemia,
endometrial carcinoma, recurrent / metastatic squamous cell
carcinoma and most relevantly, previously treated locally advanced or metastatic breast cancer (http://www.cancernetwork.com/review-article/current-clinical-trials-flavopiridol/page/0/2).